New Funding to Accelerate Scopio Labs'
Commercial Growth and Product Innovation in Full-Field Digital Cell
Morphology
PARSIPPANY, N.J. and TEL AVIV, Israel, July 25,
2024 /PRNewswire/ -- Scopio Labs, developer of
Full-Field Digital Cell Morphology imaging and analysis platforms,
today announced the successful completion of its Series D funding
round, raising $42 million. This
round was led by Fortissimo Capital, with participation from
existing investors. The newly secured capital will fuel commercial
expansion and accelerate the innovation of new products that
leverage Scopio's Full-Field technology. This Series D brings
Scopio's total fundraising to $130M.
Scopio's breakthrough platform uses computational photography to
provide unprecedented digital imaging of thousands of cells. Lab
practitioners, therefore, have a full-field view of all regions of
clinical interest on the sample at the highest resolution,
supplanting the need for manual microscopy. By harnessing the power
of clinical AI-based decision support combined with Full-Field
digital imaging, Scopio delivers unparalleled workflow efficiency
in blood cell analysis designed to enhance remote consultation and
collaboration, expedite decision-making, and bolster patient care.
This platform not only amplifies diagnostic capabilities but also
significantly curtails the time and expenses traditionally
associated with manual methods.
The Series D funding will enable Scopio to accelerate its market
penetration and expand its global footprint. This includes scaling
sales and marketing efforts and strengthening customer support. The
funding will support the continued development of Scopio Labs'
digital morphology platform and the creation of next-generation
products to meet the evolving needs of hematology laboratories and
hospitals.
"We are excited to have Fortissimo Capital lead our Series D
funding round," said Itai Hayut,
Co-founder and CEO of Scopio Labs. "This investment is a testament
to the remarkable progress we have made and the immense potential
of our technology. With the support of Fortissimo Capital and our
existing investors, we are well-positioned to revolutionize the
field of hematology and deliver unparalleled value to our
customers."
"Scopio is experiencing a defining inflection point. The
company's hematology solutions are transforming the manner in which
labs analyze blood samples. We believe Scopio Labs will become the
new global standard in digital cell morphology", said Yuval Cohen, Managing Partner at Fortissimo
Capital. "We look forward to supporting Scopio as it grows and
enhances its leading position in the market."
About Scopio Labs
Scopio Labs is the developer of Full-Field imaging fueling the
digital transformation of hematology laboratories worldwide. By
supporting laboratory scientists and clinicians with unprecedented
scale and depth in digital cell morphology, the company's platforms
enable timely detection of blood-related medical conditions,
expediting patients' access to life-saving treatments.
Scopio solves cell morphology's age-old trade-off between
resolution and field of view. Its high-resolution imaging and
embedded AI combine for more efficient remote workflow,
contributing to better diagnostics across the continuum of
care.
To learn more, visit www.scopiolabs.com.
About Fortissimo
Fortissimo Capital (www.ffcapital.com) is a leading private
equity fund in Israel investing
primarily in technology and industrial companies. Fortissimo's
investment strategy is to achieve capital appreciation through
taking a leading role and active approach in Israeli-related global
businesses that require immediate and significant change, or
stimulation of growth and by building business fundamentals to
facilitate sustainable long-term growth and value creation.
Some of Fortissimo's notable exits include: Kornit Digital IPO;
SodaStream IPO; the sale of Diptech to Ferro, the sale of Nur
Macroprinters to Hewlett Packard, the sale of Cadent to Align Inc.,
the sale of Breezometer to Google, the sale of Starhome to Telerix,
the sale of Cardo to EMK, the sale of Biological Industries to
Sartorius AG, and the sale of AOD Software Inc. to Primus
Capital.
View original
content:https://www.prnewswire.com/news-releases/scopio-labs-secures-42-million-in-funding-led-by-fortissimo-capital-302206497.html
SOURCE Scopio Labs